Nov 19, 2025 8:05 AM Eastern Standard Time Harmony Biosciences Announces Initiation of First- In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence Share BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing Topline clinical data expected in 2026 PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Hol ...